(Q44648868)

5 December 2017

title

Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome (English)

1 reference

polycystic ovary syndrome

5 December 2017

0 references

1 reference

1 reference

1 reference

Tevfik Sabuncu

1

1 reference

5 December 2017

Muge Harma

2

1 reference

5 December 2017

Mehmet Harma

3

1 reference

5 December 2017

Yasar Nazligul

4

1 reference

5 December 2017

Feryal Kilic

5

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 November 2003

1 reference

full work available at URL

5 December 2017

http://www.fertstert.org/article/S0015028203021629/pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14607575

https://api.elsevier.com/content/article/PII:S0015028203021629?httpAccept=text/xml

30 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0015-0282(03)02162-9

https://api.elsevier.com/content/article/PII:S0015028203021629?httpAccept=text/plain

30 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0015-0282(03)02162-9

30 March 2024

published in

Fertility and Sterility

1 reference

5 December 2017

volume

80

1 reference

5 December 2017

issue

5

1 reference

5 December 2017

page(s)

1199-1204

1 reference

Polycystic ovary syndrome

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Obesity, lipids, cardiovascular risk, and androgen excess

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Coronary Heart Disease Risk Factors in Women With Polycystic Ovary Syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Lipid and apolipoprotein abnormalities in hirsute women. I. The association with insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Do polycystic-appearing ovaries affect the risk of cardiovascular disease among women with polycystic ovary syndrome?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Clinical signs of androgen excess as risk factors for coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Comparison of effects of different combined oral-contraceptive formulations on carbohydrate and lipid metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Inhibitory effect of sandostatin on secretion of luteinising hormone and ovarian steroids in polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Polycystic ovarian disease: US features in 104 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Insulin and the polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Effect of body weight reduction on plasma androgens in obese, infertile women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

A study of the interactive effects of oral contraceptive use and dietary fat intake on blood pressure, cardiovascular reactivity and glucose tolerance in normotensive women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Comparative clinical evaluation of the effect on carbohydrate and lipid metabolism of two norethisterone-containing hormonal contraceptives: Mesigyna and TriNovum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Metabolic and fibrinolytic response to changed insulin sensitivity in users of oral contraceptives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Clinical efficacy and safety of cyproterone acetate in severe hirsutism: results of a multicentered Canadian study**Sponsored by the Canadian Fertility Research Association and funded by a grant-in-aid from Berlen Laboratories Limited, Canada.††T

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Managing hirsutism in gynaecological practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Treatment of hirsutism with ethinyl estradiol-desogestrel contraceptive pills has beneficial effects on the lipid profile and improves insulin sensitivity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Hirsutism: metabolic effects of two commonly used oral contraceptives and spironolactone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2803%2902162-9

Clinical review 102: Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment

7 January 2021

26

1 reference

https://api.crossref.org/works/10.1016/S0015-0282(03)02162-9

Evaluation of WHO and NDDG criteria for impaired glucose tolerance. Results from two national samples.

30 March 2024

28

1 reference

https://api.crossref.org/works/10.1016/S0015-0282(03)02162-9

30 March 2024

Identifiers

1 reference

5 December 2017

1 reference